Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Trabectedin and Durvalumab in Advanced Soft-tissue Sarcoma and Ovarian Carcinoma
NCT03085225Phase 1Completed
- Sponsor
- Institut Bergonié
- Start
- May 2017
- Primary completion
- Nov 2020
- Modality
- Antibody Conjugates, Nucleic Acid-Directed Small Molecules, Engineered Antibody Formats
- Countries
- 1
01
Overview
Phase 1, open-label trial of trabectedin and durvalumab in soft tissue sarcoma (STS) and ovarian carcinoma, sponsored by Institut Bergonié. Started May 2017; status: completed.
02
Drugs
trabectedindurvalumab
03
Conditions
soft tissue sarcoma (STS)ovarian carcinoma
Beyond the preview
Go deeper on NCT03085225.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03085225.